HRMY

Harmony Biosciences Holdings Inc

33.77

Jul 17 • 03:59PM ET +0.24 (0.72%)

33.77

Aftermarket • 05:00PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Jul 16, 11:00 AMHarmony Biosciences CFO Glenn Reicin steps down as company reiterates record preliminary Q2 WAKIX revenue and 2026 guidance

Peers: ACAD AXSM SUPN ALKS INDV ANIP KNSA LNTH AMRX NBIX

| Held by: IJR AVUV VTI VB IWM VBK VXF FESM IWO PJP

Scroll to Statements

Index	RUT
Market Cap	1.96B
Enterprise Value	1.52B
Income	145.62M
Sales	899.11M
Book/sh	15.73
Cash/sh	11.07
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	293
IPO	Aug 19, 2020

P/E	13.60
Forward P/E	8.01
PEG	0.35
P/S	2.17
P/B	2.15
P/C	3.05
P/FCF	5.72
EV/EBITDA	7.08
EV/Sales	1.69
Quick Ratio	3.56
Current Ratio	3.58
Debt/Eq	0.23
LT Debt/Eq	0.16
Option/Short	Yes / Yes

EPS (ttm)	2.48
EPS next Y	4.22
EPS next Q	0.88
EPS this Y	27.81%
EPS next Y	21.74%
EPS next 5Y	22.77%
EPS past 3/5Y	-3.00% -
Sales past 3/5Y	25.64% 40.30%
EPS Y/Y TTM	-5.53%
Sales Y/Y TTM	20.71%
EPS Q/Q	-29.00%
Sales Q/Q	16.59%
Earnings	Aug 04 BMO
EPS/Sales Surpr.	-20.83% -2.47%

Insider Own	12.98%
Insider Trans	-0.33%
Inst Own	99.73%
Inst Trans	10.61%
ROA	12.51%
ROE	17.86%
ROIC	13.82%
Gross Margin	73.90%
Oper. Margin	21.08%
Profit Margin	16.20%
SMA20	-4.99%
SMA50	1.25%
SMA200	3.56%
Trades

Shs Outstand	57.87M
Shs Float	50.38M
Short Float	9.15%
Short Ratio	5.28
Short Interest	4.61M
52W High	40.87 -17.37%
52W Low	25.52 32.33%
Volatility	4.28% 3.55%
ATR (14)	1.35
RSI (14)	43.50
Beta	0.96
Rel Volume	0.81
Avg Volume	873.85K
Volume	705,258

Perf Week	-8.33%
Perf Month	-0.18%
Perf Quarter	14.79%
Perf Half Y	-6.30%
Perf YTD	-9.75%
Perf Year	-7.30%
Perf 3Y	-7.33%
Perf 5Y	20.39%
Perf 10Y	-
Recom	2.00
Target Price	44.91
Prev Close	33.53
Price	33.77
Change	0.72%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-23-26	Downgrade	Truist	Buy → Hold
Feb-23-26	Downgrade	Deutsche Bank	Buy → Hold
Feb-11-26	Resumed	UBS	Neutral	$46
Jul-21-25	Initiated	Truist	Buy	$48
Jul-10-25	Resumed	Goldman	Neutral	$33
Jun-02-25	Resumed	Oppenheimer	Outperform	$61
Feb-11-25	Initiated	Deutsche Bank	Buy	$55
Dec-17-24	Initiated	H.C. Wainwright	Buy	$75
Oct-10-24	Resumed	Raymond James	Outperform
Sep-10-24	Initiated	UBS	Buy	$56
Jun-21-24	Initiated	Citigroup	Buy	$48
Jan-02-24	Downgrade	BofA Securities	Neutral → Underperform	$30
Sep-25-23	Downgrade	Goldman	Neutral → Sell	$40 → $31
Sep-07-23	Initiated	Berenberg	Buy	$59
Apr-20-23	Initiated	BofA Securities	Neutral	$35
Oct-14-22	Upgrade	Jefferies	Hold → Buy	$57 → $61
Oct-14-22	Upgrade	Janney	Neutral → Buy	$57 → $61
Aug-03-22	Downgrade	Jefferies	Buy → Hold	$57
Jul-13-22	Downgrade	Goldman	Buy → Neutral	$55
Jul-07-22	Initiated	Mizuho	Buy	$64

Show Previous Ratings

Jul-16-26 10:37AM	Harmony Biosciences Announces Preliminary Q2 Revenue, CFO Transition Says Executives Departure Not Due To Any Disagreement (Stocktwits)
08:30AM	Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition (Business Wire)
Jun-11-26 08:05AM	Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting (Business Wire)
Jun-04-26 01:14AM	Looking Back at Stock Picks Hyatt Hotels, Sensient Technologies, Harmony Biosciences. What the Charts Say. (Barrons.com)
May-27-26 08:05AM	Harmony Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
07:30AM	Loading…
May-07-26 07:30AM	Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities (Business Wire)
May-06-26 09:25AM	Harmony Biosciences Holdings Inc (HRMY) Q1 2026 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-23-26 08:05AM	Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 (Business Wire)
Apr-16-26 08:05AM	Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting (Business Wire)
Apr-14-26 08:05AM	Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer (Business Wire)
Apr-02-26 08:05AM	Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board (Business Wire)
Mar-31-26 08:05AM	Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-04-26 08:05AM	Harmony Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Mar-01-26 04:27AM	Deutsche Bank Cuts PT on Harmony Biosciences Holdings (HRMY) to $30 From $31 (Insider Monkey)
Feb-26-26 08:57AM	Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments (Insider Monkey)
11:03AM	Loading…
Feb-25-26 11:03AM	BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
11:01AM	IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress (Zacks)
10:21AM	RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up (Zacks)
09:12AM	Corcept's Q4 Earnings and Revenues Fall Short of Estimates (Zacks)
09:10AM	Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)
08:55AM	Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y (Zacks)
Feb-24-26 08:05PM	Harmony Biosciences Holdings, Inc. Q4 2025 Earnings Call Summary (Moby)
04:02PM	Harmony Biosciences Holdings Inc (HRMY) Q4 2025 Earnings Call Highlights: Record Revenue Growth ... (GuruFocus.com)
12:08PM	AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales (Zacks)
11:47AM	Harmony Biosciences Q4 Earnings Call Highlights (MarketBeat)
11:35AM	BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market (Zacks)
09:40AM	Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Miss Estimates (Zacks)
07:30AM	Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion (Business Wire)
Feb-23-26 11:12AM	Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues (Zacks) -7.85%
10:47AM	FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug (Zacks)
07:23AM	Loading…
07:23AM	Harmony Biosciences Holdings Inc (HRMY) Q4 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-20-26 10:20AM	Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View (Zacks) -15.21%
09:59AM	Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down (Zacks)
Feb-19-26 11:59AM	BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth (Zacks)
07:34AM	ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up (Zacks)
04:07AM	Zacks.com featured highlights include Harmony Biosciences, Tripadvisor, The AES and Concentrix (Zacks)
Feb-18-26 11:31AM	FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma (Zacks)
11:24AM	Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
10:45AM	4 Value Stocks to Buy Now Amid AI-Driven Market Volatility (Zacks)
09:41AM	EU Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients (Zacks)
09:32AM	Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo (Zacks)
07:14AM	Top 5 Bargain P/B Stocks Investors Should Watch Now (Zacks)
Feb-17-26 10:00AM	Earnings Preview: Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Expected to Decline (Zacks)
08:05AM	Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy (Business Wire)
Feb-16-26 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Harmony Biosciences (HRMY) (Zacks)
Feb-12-26 09:55AM	Wall Street Analysts Believe Harmony Biosciences (HRMY) Could Rally 26.95%: Here's is How to Trade (Zacks)
Feb-11-26 11:40AM	HRMY vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
09:40AM	Is Harmony Biosciences (HRMY) Stock Undervalued Right Now? (Zacks)
Feb-10-26 08:05AM	Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 (Business Wire)
Feb-05-26 12:56PM	Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes (Zacks)
10:22AM	Zacks.com featured highlights include Harmony Biosciences, Adecoagro, Sociedad Quimica y Minera de Chile, Angi and PHINIA (Zacks)
Feb-04-26 09:39AM	5 Value Picks Amid AI-Driven Tech Sell-Off & U.S.-Iran Tensions (Zacks)
Feb-02-26 07:20AM	5 Low Price-to-Book Stocks That Are Worth Watching in February (Zacks)
06:14AM	Zacks.com featured highlights include Harmony Biosciences, Universal Health Services, Concentrix and Global Payments (Zacks)
Jan-30-26 11:30AM	4 Value Stocks to Consider as Tech Volatility Weighs on Wall Street (Zacks)
Jan-29-26 03:00PM	4 GARP Stocks With Attractive PEG Ratios and Strong Growth Outlooks (Zacks)
12:45PM	Is Harmony Biosciences (HRMY) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
Jan-28-26 12:24PM	How Harmony Biosciences Can Prove Its Skeptics Wrong (Motley Fool)
12:21PM	Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums (Zacks)
Jan-27-26 12:22PM	Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed? (Motley Fool)
Jan-26-26 12:21PM	I Was Shocked to Find This Value-Priced Biotech Growth Stock (Motley Fool)
11:40AM	HRMY or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
09:40AM	Should Value Investors Buy Harmony Biosciences (HRMY) Stock? (Zacks)
Jan-15-26 08:47AM	Buy These 5 Price-to-Book Value Stocks for Gains in 2026 (Zacks)
Jan-13-26 12:45PM	Harmony Biosciences (HRMY) is an Incredible Growth Stock: 3 Reasons Why (Zacks) -6.56%
Jan-12-26 08:05AM	Harmony Biosciences Guides to Over $1 Billion in WAKIX Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation (Business Wire)
Jan-08-26 11:40AM	HRMY vs. LQDA: Which Stock Is the Better Value Option? (Zacks)
09:40AM	Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now? (Zacks)
Jan-07-26 08:05AM	Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-08-25 08:05AM	Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome (Business Wire)
Dec-02-25 08:05AM	Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting (Business Wire)
Nov-24-25 08:05AM	Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation (Business Wire)
Nov-19-25 08:05AM	Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence (Business Wire)
Nov-18-25 08:05AM	Harmony Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Nov-05-25 08:01AM	Harmony Biosciences Holdings Inc (HRMY) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Nov-04-25 08:40AM	Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings Miss Estimates (Zacks)
07:30AM	Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M (Business Wire)
Nov-03-25 07:38AM	Earnings To Watch: Harmony Biosciences Holdings Inc (HRMY) Reports Q3 2025 Result (GuruFocus.com)
Oct-31-25 10:29PM	Truist Financial Reiterates a Buy on Harmony Biosciences (HRMY) (Insider Monkey)
Oct-29-25 10:00AM	Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q3 Earnings Expected to Decline (Zacks)
Oct-28-25 10:00AM	Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-24-25 04:38AM	Harmony Biosciences (HRMY) Moves 12.7% Higher: Will This Strength Last? (Zacks)
Oct-23-25 08:05AM	Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance (Business Wire) +12.68%
Oct-09-25 05:10PM	Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Sep-29-25 06:54PM	H.C. Wainwright Reaffirms Buy on Harmony Biosciences Holdings, Inc. (HRMY) Despite Phase 3 Setback (Insider Monkey)
Sep-25-25 09:59AM	HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal (Zacks)
Sep-24-25 01:20PM	Harmony Biosciences' Genetic Disorder Drug Disappoints In Phase 3 Study (Benzinga) -16.56%
01:02PM	Harmony Biosciences Whiffs In 'Undruggable' Genetic Disease; Shares Tumble (Investor's Business Daily)
08:00AM	Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome (Business Wire)
Sep-17-25 02:27PM	UBS Maintains a Buy Rating on Harmony Biosciences Holdings (HRMY), Sets a $50 PT (Insider Monkey)
Sep-15-25 02:18PM	11 fast-growing small-cap stocks that could get a boost from the Fed's next move (MarketWatch)
Aug-29-25 05:00AM	Harmony Biosciences Holdings, Inc. (HRMY) Expands WAKIX With FDA Nod for Prader-Willi (Insider Monkey)
Aug-26-25 08:05AM	Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress (Business Wire)
Aug-21-25 08:05AM	Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference (Business Wire)
Aug-12-25 09:11AM	H.C. Wainwright Remains a Buy on Harmony Biosciences Holdings (HRMY) (Insider Monkey)
Aug-08-25 10:15AM	Can Cannabis Stocks Reverse Their Prolonged Downtrend? (Zacks)
Aug-05-25 08:40AM	Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates (Zacks)
07:30AM	Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025 (Business Wire)
Aug-04-25 04:35PM	Harmony Biosciences Holdings, Inc. (HRMY): A Bull Case Theory (Insider Monkey)
09:36AM	Harmony Biosciences Holdings Inc (HRMY) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Founder & Non-Executive ChairmanMr. Jeffrey S. Aronin

PresidentDr. Jeffrey M. Dayno M.D.

Chief Operating OfficerMr. Peter Anastasiou

M.S.Dr. Kumar Budur M.D.

M.B.A.Mr. Andrew Serafin J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SANDIP KAPADIA	Former Officer	Jul 02 '26	Proposed Sale	36.96	25,000	924,008		Jul 02 04:06 PM
SANDIP KAPADIA	Former Officer	Jun 30 '26	Proposed Sale	36.08	50,000	1,803,825		Jun 30 04:04 PM
SANDIP KAPADIA	Former Officer	Jun 26 '26	Proposed Sale	35.24	45,594	1,606,824		Jun 26 04:17 PM
SANDIP KAPADIA	Former Officer	Jun 24 '26	Proposed Sale	35.02	4,406	154,302		Jun 24 04:18 PM
SANDIP KAPADIA	Former Officer	Jun 09 '26	Proposed Sale	33.74	27,960	943,264		Jun 09 04:28 PM
SANDIP KAPADIA	Former Officer	Jun 05 '26	Proposed Sale	33.08	2,101	69,504		Jun 05 04:13 PM
SANDIP KAPADIA	Former Officer	Jun 04 '26	Proposed Sale	33.02	7,064	233,232		Jun 04 04:23 PM
Budur Kumar	CHIEF MEDICAL OFFICER	May 01 '26	Option Exercise	0.00	18,750	0	32,997	May 18 04:14 PM
SANDIP KAPADIA	Former Officer	May 08 '26	Proposed Sale	31.51	45,481	1,433,056		May 08 04:08 PM
Zaeske Adam H.	CHIEF COMMERCIAL OFFICER	Apr 07 '26	Option Exercise	0.00	7,500	0	7,500	Apr 09 04:15 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Jan 26 '26	Sale	37.15	3,746	139,171	24,521	Jan 28 08:19 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Jan 25 '26	Option Exercise	0.00	4,725	0	4,725	Jan 26 04:49 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Jan 24 '26	Option Exercise	0.00	3,813	0	3,813	Jan 26 04:49 PM
Serafin Andrew	CHIEF STRATEGY OFFICER	Jan 25 '26	Option Exercise	0.00	2,600	0	2,600	Jan 26 04:48 PM
Serafin Andrew	CHIEF STRATEGY OFFICER	Jan 24 '26	Option Exercise	0.00	2,500	0	2,500	Jan 26 04:48 PM
Budur Kumar	CHIEF MEDICAL OFFICER	Jan 25 '26	Option Exercise	0.00	2,662	0	2,662	Jan 26 04:45 PM
Budur Kumar	CHIEF MEDICAL OFFICER	Jan 24 '26	Option Exercise	0.00	2,188	0	2,188	Jan 26 04:45 PM
Dayno Jeffrey M.	PRESIDENT, CEO	Jan 25 '26	Option Exercise	0.00	13,000	0	13,000	Jan 26 04:43 PM
Dayno Jeffrey M.	PRESIDENT, CEO	Jan 24 '26	Option Exercise	0.00	10,500	0	10,500	Jan 26 04:43 PM
SANDIP KAPADIA	Officer	Jan 26 '26	Proposed Sale	36.82	3,746	137,928		Jan 26 04:30 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Jan 15 '26	Sale	35.92	20,961	752,833	0	Jan 20 08:39 PM
SANDIP KAPADIA	Officer	Jan 15 '26	Proposed Sale	36.04	20,961	755,434		Jan 15 04:22 PM
Dayno Jeffrey M.	PRESIDENT, CEO	Dec 12 '25	Option Exercise	8.22	20,000	164,400	20,000	Dec 17 05:25 PM
Dayno Jeffrey M.	PRESIDENT, CEO	Dec 12 '25	Sale	40.11	25,933	1,040,103	0	Dec 17 05:25 PM
JEFFREY M DAYNO	Director	Dec 12 '25	Proposed Sale	39.59	25,933	1,026,687		Dec 12 04:25 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Dec 05 '25	Option Exercise	29.03	20,000	580,600	20,000	Dec 09 04:10 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Dec 05 '25	Sale	39.54	20,000	790,896	0	Dec 09 04:10 PM
SANDIP KAPADIA	Officer	Dec 05 '25	Proposed Sale	38.25	20,000	765,000		Dec 05 04:30 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Nov 21 '25	Sale	35.00	3,427	119,945	0	Nov 25 04:10 PM
SANDIP KAPADIA	Officer	Nov 21 '25	Proposed Sale	33.39	3,427	114,428		Nov 21 04:46 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Sep 30 '25	Option Exercise	0.00	45,000	0	45,000	Oct 02 04:05 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Aug 15 '25	Sale	36.50	21,573	787,378	0	Aug 19 04:15 PM
SANDIP KAPADIA	Officer	Aug 15 '25	Proposed Sale	36.51	21,573	787,630		Aug 15 04:28 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HRMY

Harmony Biosciences Holdings Inc

Upgrade your Finviz experience